Administrative Core

Goal & Research Areas

The Administrative Core has primary responsibility for managing, coordinating, and supervising all center activities. It organizes monthly oversight meetings for each project with the Scientific Advisory Committee. There are also monthly research presentations made to the entire Center. The admin core monitors research progress of all projects, performance of cores, and ensures that all required progress reports and invention disclosures are submitted in a timely fashion. It has primary responsibility for the scientific content of the annual Stanford AViDD Center retreat and research agenda to be presented at the annual reverse site visits. It is responsible for maintaining appropriate communication with NIAID program staff and monitors the individual budgets of each Project and Core and evaluates the progress in conjunction with the established aims and timelines. It is responsible for approving and coordinating any re-budgeting of funds required for the research needs of the individual projects, as well as directing the research-related travel guidelines. The Administrative Core also coordinates the regularly scheduled meetings of each Project with their External Advisors.

The Center’s organization is designed to promote a maximal collaborative and synergistic environment because the PI believes that innovation happens at the intersection of respective expertise within the context of interdisciplinary teams. This begins with each of the projects supported by the Administrative Core including multiple faculty with different but complementary expertise. The monthly meeting of all Center members helps maximize collaborative opportunities not only within projects, but also between projects. In addition, the PI will seek to maximize opportunities for communication and collaboration with other AViDD Centers.

Core Leader & Team

Chris Bodurow

Chris Bodurow

Learn More Learn More
Jeffrey Glenn

Jeffrey Glenn

Learn More Learn More
Natalie McClure

Natalie McClure

Learn More Learn More
Sharon Collum

Sharon Collum

Donna Medved

Donna Medved

Hot Topic

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...

Read More Learn More
Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.

Read More Learn More
Antiviral Program for Pandemics

Antiviral Program for Pandemics

The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.

Read More Learn More
ChrisBodurow
Chris Bodurow Ph.D Deputy Director and Chief Operating Officer, AVIDD/SyneRX

Chris has a proven record of accomplishment delivering results to pharmaceutical and scientific organizations, including 33 years of management experience at Eli Lilly and Company, within Lilly Research Laboratories (LRL), 3.5 years in a global leadership role at IQVIA, and now as Deputy Director and COO of a significant NIH/NIAID research grant at Stanford University Medical School.

Over the years, Chris has served as a leader of multiple global teams in drug development and R&D Operations, representing her organizations in multiple external settings, including scientific, academic, drug development and R&D Operations forums.

In, December 2017, Chris retired from Lilly as Sr. Director, External Sourcing, leading an enterprise-wide R&D operations group that partnered with LRL functions to assess, on-board, and govern third party organizations across the entire drug development value chain, from pre-clinical, through clinical, regulatory, safety, health outcomes, product and device development, and diagnostics. The division consolidated both corporate and external requirements to deliver high-quality, risk-based, third party governance, oversight and alliance management for the LRL Development organization.

In February 2019, Chris joined IQVIA as the Vice-President of Strategy & Operations for DSSR, and subsequently moved in the role of Vice-President, Global Regulatory Affairs.

Specialties: Pharmaceutical Development, R&D Operations, Molecule Submission/Approval/Launch, Product Lifecycle Planning and Development, R&D Business Systems design and delivery. Third Party Management, Women's Leadership Development.

EdwardPham
Jeffrey Glenn MD/PhD, U.C.S.F Director ViRx@Stanford; Professor of Medicine/Microbiology and Immunology, Stanford University School of Medicine, Director, ViRx@Stanford

Dr. Jeffrey Glenn is a Professor of Medicine, Microbiology & Immunology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He is the founder of Eiger Biopharmaceuticals who is developing Lambda for hepatitis delta and COVID.

Dr. Glenn is an author on over 100 scientific articles and book chapters, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. He is the principal investigator on multiple NIH grants, and a member of FDA Antiviral Drugs.

He is an international authority on developing novel antiviral therapeutics.